# Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma

> **NIH NIH R01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $453,875

## Abstract

SUMMARY
SOX2 is a cell fate–determining transcription factor that is expressed in ~70% of cutaneous and head and neck
squamous cell carcinomas (SCCs) in patients. SOX2 is highly enriched in stem cell–like tumor-propagating cells
(TPCs), which are located within the basal SCC layer where they can self-renew or differentiate into suprabasal
SCC cells without proliferative potential. Although we know SOX2 controls the fate choice between TPC self-
renewal and squamous differentiation, it is unclear how its activity is regulated in SCCs and whether these
regulatory mechanisms could be developed into therapies for cancer patients. Here, we propose to test the
hypothesis that phosphorylation of SOX2 inhibits its activity, perturbs the SCC-specific SOX2-PITX1-
TP63 self-renewal circuit that drives clonal expansion and SCC growth, and thereby restores the KLF4-
dependent squamous differentiation program in SCCs. Our hypothesis is based on our preliminary studies,
which showed that SOX2 can be phosphorylated and that this phosphorylation attenuates its activity in SCC
cells. We propose to 1) test if SOX2 phosphorylation inhibits TPC self-renewal, clonal expansion, and SCC
growth; 2) identify the kinases and phosphatases that regulate SOX2 phosphorylation and function; and 3) define
the molecular mechanisms by which SOX2 activity governs TPC self-renewal, SCC growth, and differentiation
in mouse and patient-derived SCC models. We expect our proposed research will explain the fate choice
between TPC self-renewal and terminal differentiation on a molecular level and therefore provide new concepts
for the rational development of pharmacological approaches that enforce the commitment of TPCs to terminally
differentiate into SCC cells without proliferative potential.

## Key facts

- **NIH application ID:** 10120124
- **Project number:** 1R01CA248175-01A1
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Markus Schober
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $453,875
- **Award type:** 1
- **Project period:** 2020-12-01 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10120124

## Citation

> US National Institutes of Health, RePORTER application 10120124, Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma (1R01CA248175-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10120124. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*